Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.

Abstract

In an open-label, 24-month trial, 721 de novo heart transplant recipients were randomized to everolimus 1.5 mg or 3.0 mg with reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine (plus corticosteroids ± induction). Primary efficacy endpoint was the 12-month composite incidence of biopsy-proven acute rejection… (More)
DOI: 10.1111/ajt.12181

Topics

Cite this paper

@article{Eisen2013EverolimusVM, title={Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.}, author={Howard Jay Eisen and Jon Kobashigawa and Randall C. Starling and Daniel F. Pauly and Alain Kfoury and Heather J. Ross and S S Wang and Bernard Cantin and Adrian B. Van Bakel and Greg A Ewald and Stefan Hirt and Hans Brendan Lehmkuhl and Anne M. Keogh and Max L Rinaldi and Luciano Potena and Andreas Zuckermann and Guiyun Dong and Catherine Cornu-Artis and P Mondejar Lopez}, journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons}, year={2013}, volume={13 5}, pages={1203-16} }